首页
/
/
/
ALK
/
ALK inhibitor 2
ALK inhibitor 2
{[allProObj[0].p_purity_real_show]}
货号：A524942
ALK inhibitor 2 is a selective inhibitor for the ALK kinase.
ALK inhibitor 2 化学结构
ALK inhibitor 2 3D分子结构
规格
价格
会员价
库存
数量
{[ item.pr_size ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]}
{[ getRatePrice(item.pr_rmb_sale, 1,1) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]}
{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]}
{[ getRatePrice(item.pr_rmb_sale, 1,1) ]}
{[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]}
{[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}
现货
咨询
-
+
ALK inhibitor 2 质控信息
ASP3026
+
{[allProObj[0].p_purity_real_show]}
ALK-IN-1
++++
{[allProObj[0].p_purity_real_show]}
Crizotinib
++++
ROS1, Ki: <0.025 nM
ALK, IC50: 24 nM
{[allProObj[0].p_purity_real_show]}
Entrectinib
✔
{[allProObj[0].p_purity_real_show]}
Brigatinib
+++
ROS1, IC50: 1.9 nM
ALK, IC50: 0.37 nM
FLT3
{[allProObj[0].p_purity_real_show]}
NVP-TAE 684
+
{[allProObj[0].p_purity_real_show]}
Alectinib
++
ALK, IC50: 1.9 nM
ALK (F1174L), IC50: 3.5 nM
{[allProObj[0].p_purity_real_show]}
Ceritinib
+++
Insulin Receptor,IGF-1R
{[allProObj[0].p_purity_real_show]}
GSK1838705A
+++
Insulin Receptor,IGF-1R
{[allProObj[0].p_purity_real_show]}
AZD-3463
++
IGF-1R
{[allProObj[0].p_purity_real_show]}
Lorlatinib
++++
ROS1, Ki: <0.07 nM
ALK (L1196M), Ki: 0.07 nM
{[allProObj[0].p_purity_real_show]}
Repotrectinib
+
ALK(L1196M), IC50: 1.01 nM
ALK(G1202R), IC50: 1.26 nM
Src
{[allProObj[0].p_purity_real_show]}
Belizatinib
++
{[allProObj[0].p_purity_real_show]}
展开
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。
ALK inhibitor 2 生物活性
描述
Anaplastic lymphoma kinase (ALK) encodes a highly conserved receptor tyrosine kinase (RTK) within the insulin receptor superfamily, comprised of an extracellular domain, a single-pass transmembrane region, and an intracellular kinase domain[2] [3] [4]
ALK inhibitor 2 参考文献
[1] US20130096100
[2] Lin JJ, Riely GJ, Shaw AT. Targeting ALK: Precision Medicine Takes on Drug Resistance. Cancer Discov. 2017 Feb;7(2):137-155. doi: 10.1158/2159-8290.CD-16-1123. Epub 2017 Jan 25. PMID: 28122866; PMCID: PMC5296241.
[3] Palmer RH, Vernersson E, Grabbe C, Hallberg B. Anaplastic lymphoma kinase: signalling in development and disease. Biochem J. 2009 May 27;420(3):345-61. doi: 10.1042/BJ20090387. PMID: 19459784; PMCID: PMC2708929.
[4] Marsilje TH, Pei W, Chen B, Lu W, Uno T, Jin Y, Jiang T, Kim S, Li N, Warmuth M, Sarkisova Y, Sun F, Steffy A, Pferdekamper AC, Li AG, Joseph SB, Kim Y, Liu B, Tuntland T, Cui X, Gray NS, Steensma R, Wan Y, Jiang J, Chopiuk G, Li J, Gordon WP, Richmond W, Johnson K, Chang J, Groessl T, He YQ, Phimister A, Aycinena A, Lee CC, Bursulaya B, Karanewsky DS, Seidel HM, Harris JL, Michellys PY. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem. 2013 Jul 25;56(14):5675-90. doi: 10.1021/jm400402q. Epub 2013 Jun 26. PMID: 23742252.
展开
ALK inhibitor 2 实验方案
计算器
摩尔计算器
总药量计算器
工作液计算器
存储液制备
1mg
5mg
10mg
1 mM
5 mM
10 mM
1.93mL
0.39mL
0.19mL
9.65mL
1.93mL
0.97mL
19.30mL
3.86mL
1.93mL
ALK inhibitor 2 技术信息
搜索
